Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

649
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
649

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microencapsulated sodium nitrite is a humane solution for domestic grower pig depopulation during an emergency animal disease response.

Australian veterinary journal·2025
Same author

Antarctic Krill with parasites grow slower than uninfected peers.

Marine biology·2025
Same author

Enhancing pressurized esports performance: a pilot study on the combined effects of transcranial direct current stimulation and arousal reappraisal.

Anxiety, stress, and coping·2025
Same author

Managing free-roaming domestic dog populations using surgical sterilisation: a randomised controlled trial.

Scientific reports·2025
Same author

Antarctic krill vertical migrations modulate seasonal carbon export.

Science (New York, N.Y.)·2025
Same author

Reliability of a novel point of care device for monitoring diabetic peripheral neuropathy.

Scientific reports·2023
Same journal

Bilateral macronodular and micronodular hyperplasia: Biochemical, radiological and genetic diagnosis.

Vitamins and hormones·2026
Same journal

ACTH independent Cushing's syndrome: Diagnosis and etiology.

Vitamins and hormones·2026
Same journal

Biochemical diagnosis of hypercortisolism: When and how?

Vitamins and hormones·2026
Same journal

New tools for the diagnosis of hypercortisolism.

Vitamins and hormones·2026
Same journal

Cardiometabolic comorbidities in overt Cushing's syndrome.

Vitamins and hormones·2026
Same journal

Molecular profile of Cushing's syndrome.

Vitamins and hormones·2026
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

Isolation and Transplantation of Different Aged Murine Thymic Grafts.
05:47

Isolation and Transplantation of Different Aged Murine Thymic Grafts.

Published on: May 13, 2015

14.7K

Immune Modulation with Thymosin Alpha 1 Treatment.

R King1, C Tuthill1

  • 1SciClone Pharmaceuticals, Inc., Foster City, CA, United States.

Vitamins and Hormones
|July 25, 2016
PubMed
Summary
This summary is machine-generated.

Thymosin alpha 1 (Ta1) restores immune function by activating immune cells and cytokine production. This peptide shows potential for treating immune suppression from aging, infection, or cancer.

Keywords:
Cancer treatmentImmune modulationInfectious disease treatmentThymalfasinThymosin alpha 1Vaccine enhancement

More Related Videos

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

616
Determination of Regulatory T Cell Subsets in Murine Thymus, Pancreatic Draining Lymph Node and Spleen Using Flow Cytometry
08:06

Determination of Regulatory T Cell Subsets in Murine Thymus, Pancreatic Draining Lymph Node and Spleen Using Flow Cytometry

Published on: February 27, 2019

12.4K

Related Experiment Videos

Last Updated: Mar 17, 2026

Isolation and Transplantation of Different Aged Murine Thymic Grafts.
05:47

Isolation and Transplantation of Different Aged Murine Thymic Grafts.

Published on: May 13, 2015

14.7K
Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

616
Determination of Regulatory T Cell Subsets in Murine Thymus, Pancreatic Draining Lymph Node and Spleen Using Flow Cytometry
08:06

Determination of Regulatory T Cell Subsets in Murine Thymus, Pancreatic Draining Lymph Node and Spleen Using Flow Cytometry

Published on: February 27, 2019

12.4K

Area of Science:

  • Immunology
  • Peptide Science
  • Molecular Biology

Background:

  • Thymosin alpha 1 (Ta1) is a peptide derived from thymus tissue.
  • It was identified for its ability to restore immune function in thymectomized mice.
  • Ta1 exhibits a pleiotropic mechanism, impacting various immune cell subsets involved in immune suppression.

Purpose of the Study:

  • To summarize extensive preclinical and clinical studies on Thymosin alpha 1 (Ta1).
  • To highlight the immune-stimulating effects and therapeutic potential of Ta1.
  • To explore Ta1's utility in treating immune suppression associated with aging, infection, and cancer.

Main Methods:

  • Ta1 acts via Toll-like receptors on myeloid and plasmacytoid dendritic cells.
  • Activation of signaling pathways and cytokine production are key mechanisms.
  • Studies involved both preclinical models and clinical trials.

Main Results:

  • Ta1 demonstrated significant improvements in immune system cell subsets.
  • Evidence supports Ta1's role in activating dendritic cells and stimulating cytokine production.
  • Preclinical and clinical data indicate broad therapeutic potential.

Conclusions:

  • Thymosin alpha 1 (Ta1) is a potent immune-stimulating peptide.
  • Ta1 shows promise for treating diverse conditions characterized by immune suppression.
  • Further research supports Ta1's application in managing age-related immune decline, infections, and cancer.